Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.

被引：9
|
作者：
Malhotra, Jyoti
Jabbour, Salma
Orlick, Michelle
Riedlinger, Gregory
Joshi, Sonali
Guo, Jessie Yanxiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21138
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of mitonafide in non-small cell lung cancer (NSCLC)
    Casado, A
    Rosell, R
    GarciaGomez, R
    DiazRubio, E
    PerezManga, G
    Font, A
    Benavides, A
    Martin, M
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 415 - 417
  • [42] A phase II study of vinorelbine in patients with advanced non-small cell lung cancer
    Evans, TRJ
    Mansi, JL
    Morgan, DAL
    Gyi, KM
    Banham, SW
    Milroy, R
    ONCOLOGY REPORTS, 1997, 4 (06) : 1337 - 1341
  • [43] Phase II study of dasatinib in patients with advanced non-small cell lung cancer
    Johnson, F. M.
    Bekele, B. N.
    Feng, L.
    Wistuba, I. I.
    Tang, X.
    Tran, H. T.
    Erasmus, J. J.
    Hwang, L.
    Takebe, N.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study.
    Milton, DT
    Miller, VA
    Azzoli, CG
    Dunne, M
    Gomez, JE
    Heelan, R
    Krug, LM
    Ramies, D
    Rizvi, NA
    Kris, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 637S - 637S
  • [45] Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
    Gray, Jhanelle E.
    Saltos, Andreas
    Tanvetyanon, Tawee
    Haura, Eric B.
    Creelan, Ben
    Antonia, Scott J.
    Shafique, Michael
    Zheng, Hong
    Dai, Wenjie
    Saller, James J.
    Chen, Zhihua
    Tchekmedyian, Nishan
    Goas, Kristen
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6623 - 6632
  • [46] Measures of aggressive care in advanced non-small cell lung cancer (NSCLC) patients
    McCannon, J.
    Jackson, V. A.
    Billings, J. A.
    Pirl, W. F.
    Greer, J.
    Lynch, T. J.
    Temel, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] FUNCTIONAL DECLINE IN PATIENTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
    Murnane, A.
    Krishnasamy, M.
    Denehy, L.
    Granger, C.
    Aranda, S.
    Mileshkin, L.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : S27 - S28
  • [48] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [49] Comorbidity and survival in advanced non-small cell lung cancer (NSCLC) veteran patients
    Chang, V. T.
    Hoover, D. R.
    Cogswell, J.
    Cholankeril, M.
    Badin, S.
    Yang, W.
    Yan, H.
    Gonzalez, M. L.
    Einhorn, J.
    Kasimis, B. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Weekly paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC).
    Nakagawa, K
    Fukuoka, M
    Saijo, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 704S - 704S
12345